Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 13 Mar 2021)

 

Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis
Jane J. Kim, Kate T. Simms, James Killen, Megan A. Smith, Emily A. Burger, Stephen Sy, Catherine Regan, Karen Canfell
Research Article | published 11 Mar 2021 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1003534
…A nonavalent human papillomavirus (HPV) vaccine has been licensed for use in women and men up to age 45 years in the United States. The cost-effectiveness of HPV vaccination for women and men aged 30 to 45 years in the context of cervical cancer screening practice was evaluated to inform national guidelines…Our results from 2 independent models suggest that HPV vaccination for adult women and men aged 30 to 45 years is unlikely to represent good value for money in the US.